Lydia Wachsmuth
University of Münster
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lydia Wachsmuth.
Journal of Cerebral Blood Flow and Metabolism | 2015
Bastian Zinnhardt; Thomas Viel; Lydia Wachsmuth; Alexis Vrachimis; Stefan Wagner; Hans-Jörg Breyholz; Andreas Faust; Sven Hermann; Klaus Kopka; Cornelius Faber; Frédéric Dollé; Sabina Pappatà; Anna M. Planas; Bertrand Tavitian; Michael Schäfers; Lydia Sorokin; Michael T. Kuhlmann; Andreas H. Jacobs
Stroke is the most common cause of death and disability from neurologic disease in humans. Activation of microglia and matrix metalloproteinases (MMPs) is involved in positively and negatively affecting stroke outcome. Novel, noninvasive, multimodal imaging methods visualizing microglial and MMP alterations were employed. The spatio-temporal dynamics of these parameters were studied in relation to blood flow changes. Micro positron emission tomography (μPET) using [18F]BR-351 showed MMP activity within the first days after transient middle cerebral artery occlusion (tMCAo), followed by increased [18F]DPA-714 uptake as a marker for microglia activation with a maximum at 14 days after tMCAo. The inflammatory response was spatially located in the infarct core and in adjacent (penumbral) tissue. For the first time, multimodal imaging based on PET, single photon emission computed tomography, and magnetic resonance imaging revealed insight into the spatio-temporal distribution of critical parameters of poststroke inflammation. This allows further evaluation of novel treatment paradigms targeting the postischemic inflammation.
The Journal of Nuclear Medicine | 2014
Sonja Schelhaas; Lydia Wachsmuth; Thomas Viel; Davina Jean Honess; Kathrin Heinzmann; Donna-Michelle Smith; Sven Hermann; Stefan Wagner; Michael T. Kuhlmann; Carsten Müller-Tidow; Klaus Kopka; Otmar Schober; Michael Schäfers; Richard Schneider; Eric O. Aboagye; John R. Griffiths; Cornelius Faber; Andreas H. Jacobs
Molecular imaging allows the noninvasive assessment of cancer progression and response to therapy. The aim of this study was to investigate molecular and cellular determinants of 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET and diffusion-weighted (DW) MR imaging in lung carcinoma xenografts. Methods: Four lung cancer cell lines (A549, HTB56, EBC1, and H1975) were subcutaneously implanted in nude mice, and growth was followed by caliper measurements. Glucose uptake and tumor proliferation were determined by 18F-FDG and 18F-FLT PET, respectively. T2-weighted MR imaging was performed, and the apparent diffusion coefficient (ADC) was determined by DW MR imaging as an indicator of cell death. Imaging findings were correlated to histology with markers for tumor proliferation (Ki67, 5-bromo-2′-deoxyuridine [BrdU]) and cell death (caspase-3, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling). The expression of human equilibrative nucleoside transporter 1 (hENT1), thymidine kinase 1 (TK1), thymidylate synthase, and thymidine phosphorylase (TP) were analyzed by Western blot and immunohistochemistry. Thymidine levels were determined by liquid chromatography–mass spectrometry. Results: Xenografts varied with respect to in vivo growth rates. MR imaging and PET revealed intratumoral heterogeneities, which were confirmed by histology. 18F-FLT uptake differed significantly between tumor lines, with A549 and H1975 demonstrating the highest radiotracer accumulation (A549, 8.5 ± 3.2; HTB56, 4.4 ± 0.7; EBC1, 4.4 ± 1.2; and H1975, 12.1 ± 3.5 maximal percentage injected dose per milliliter). In contrast, differences in 18F-FDG uptake were only marginal. No clear relationship between 18F-FLT accumulation and immunohistochemical markers for tumor proliferation (Ki67, BrdU) as well as hENT1, TK1, or TS expression was detected. However, TP was highly expressed in A549 and H1975 xenografts, which was accompanied by low tumor thymidine concentrations, suggesting that tumor thymidine levels influence 18F-FLT uptake in the tumor models investigated. MR imaging revealed higher ADC values within proliferative regions of H1975 and A549 tumors than in HTB56 and EBC1. These ADC values were negatively correlated with cell density but not directly related to cell death. Conclusion: A direct relationship of 18F-FLT with proliferation or ADC with cell death might be complicated by the interplay of multiple processes at the cellular and physiologic levels in untreated tumors. This issue must be considered when using these imaging modalities in preclinical or clinical settings.
PLOS ONE | 2013
Thomas Viel; Sonja Schelhaas; Stefan Wagner; Lydia Wachsmuth; Katrin Schwegmann; Michael T. Kuhlmann; Cornelius Faber; Klaus Kopka; Michael Schäfers; Andreas H. Jacobs
Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM). However, there is uncertainty regarding the effectiveness of TMZ. Considering the rapid evolution of the disease, methods to assess TMZ efficacy early during treatment would be of great benefit. Our aim was to monitor early effects of TMZ in a mouse model of GBM using positron emission tomography (PET) with 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). Methods Human glioma cells sensitive to TMZ (Gli36dEGFR-1) were treated with sub-lethal doses of TMZ to obtain cells with lower sensitivity to TMZ (Gli36dEGFR-2), as measured by growth and clonogenic assays. Gli36dEGFR-1 and Gli36dEGFR-2 cells were subcutaneously (s.c.) or intracranially (i.c.) xenografted into nude mice. Mice were treated for 7 days with daily injection of 25 or 50 mg/kg TMZ. Treatment efficacy was measured using [18F]FLT-PET before treatment and after 2 days. Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) were used to determine tumor volumes before treatment and after 7 days. Results A significant difference was observed between TMZ and DMSO treated tumors in terms of variations of [18F]FLT T/B ratio as soon as day 2 in the i.c. as well as in the s.c. mouse model. Variations of [18F]FLT T/B uptake ratio between days 0 and 2 correlated with variations of tumor size between days 0 and 7 (s.c. model: ntumor = 17 in nmice = 11, P<0.01; i.c. model: ntumor/mice = 9, P<0.01). Conclusions Our results indicate that [18F]FLT-PET may be useful for an early evaluation of the response of GBM to TMZ chemotherapy in patients with glioma.
Cancer Research | 2017
Bastian Zinnhardt; Hayet Pigeon; Benoit Thézé; Thomas Viel; Lydia Wachsmuth; Inga B. Fricke; Sonja Schelhaas; Lisa Honold; Katrin Schwegmann; Stefan Wagner; Andreas Faust; Cornelius Faber; Michael T. Kuhlmann; Sven Hermann; Michael Schäfers; Alexandra Winkeler; Andreas H. Jacobs
The tumor microenvironment is highly heterogeneous. For gliomas, the tumor-associated inflammatory response is pivotal to support growth and invasion. Factors of glioma growth, inflammation, and invasion, such as the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific imaging biomarkers of the glioma microenvironment. In this study, noninvasive imaging by PET with [18F]DPA-714 (TSPO) and [18F]BR-351 (MMP) was used for the assessment of localization and quantification of the expression of TSPO and MMP. Imaging was performed in addition to established clinical imaging biomarker of active tumor volume ([18F]FET) in conjunction with MRI. We hypothesized that each imaging biomarker revealed distinct areas of the heterogeneous glioma tissue in a mouse model of human glioma. Tracers were found to be increased 1.4- to 1.7-fold, with [18F]FET showing the biggest volume as depicted by a thresholding-based, volumes of interest analysis. Tumor areas, which could not be detected by a single tracer and/or MRI parameter alone, were measured. Specific compartments of [18F]DPA-714 (14%) and [18F]BR-351 (11%) volumes along the tumor rim could be identified. [18F]DPA-714 (TSPO) and [18F]BR-351 (MMP) matched with histology. Glioma-associated microglia/macrophages (GAM) were identified as TSPO and MMP sources. Multitracer and multimodal molecular imaging approaches may allow us to gain important insights into glioma-associated inflammation (GAM, MMP). Moreover, this noninvasive technique enables characterization of the glioma microenvironment with respect to the disease-driving cellular compartments at the various disease stages. Cancer Res; 77(8); 1831-41. ©2017 AACR.
Arthritis & Rheumatism | 2013
Eugen Retser; Tanja Schied; Boris V. Skryabin; Thomas Vogl; Janos M. Kanczler; Nina Hamann; Anja Niehoff; Sven Hermann; Michel Eisenblätter; Lydia Wachsmuth; Thomas Pap; Peter L. E. M. van Lent; Karin Loser; J. Roth; Frank Zaucke; Stephan Ludwig; Viktor Wixler
Objective To generate doxycycline-inducible human tumor necrosis factor α (TNFα)–transgenic mice to overcome a major disadvantage of existing transgenic mice with constitutive expression of TNFα, which is the limitation in crossing them with various knockout or transgenic mice. Methods A transgenic mouse line that expresses the human TNFα cytokine exclusively after doxycycline administration was generated and analyzed for the onset of diseases. Results Doxycycline-inducible human TNFα–transgenic mice developed an inflammatory arthritis– and psoriasis-like phenotype, with fore and hind paws being prominently affected. The formation of “sausage digits” with characteristic involvement of the distal interphalangeal joints and nail malformation was observed. Synovial hyperplasia, enthesitis, cartilage and bone alterations, formation of pannus tissue, and inflammation of the skin epidermis and nail matrix appeared as early as 1 week after the treatment of mice with doxycycline and became aggravated over time. The abrogation of human TNFα expression by the removal of doxycycline 6 weeks after beginning stimulation resulted in fast resolution of the most advanced macroscopic and histologic disorders, and 3–6 weeks later, only minimal signs of disease were visible. Conclusion Upon doxycycline administration, the doxycycline-inducible human TNFα–transgenic mouse displays the major features of inflammatory arthritis. It represents a unique animal model for studying the molecular mechanisms of arthritis, especially the early phases of disease genesis and tissue remodeling steps upon abrogation of TNFα expression. Furthermore, unlimited crossing of doxycycline-inducible human TNFα–transgenic mice with various knockout or transgenic mice opens new possibilities for unraveling the role of various signaling molecules acting in concert with TNFα.
Magnetic Resonance in Medicine | 2017
Florian Schmid; Lydia Wachsmuth; Franziska Albers; Miriam Schwalm; Albrecht Stroh; Cornelius Faber
Optogenetic fMRI (ofMRI) is a novel tool in neurophysiology and neuroimaging. The method is prone to light‐induced artifacts, two of which were investigated in this study.
Journal of Cerebral Blood Flow and Metabolism | 2016
Florian Schmid; Lydia Wachsmuth; Miriam Schwalm; Pierre-Hugues Prouvot; Eduardo Rosales Jubal; Consuelo Fois; Gautam Pramanik; Claus Zimmer; Cornelius Faber; Albrecht Stroh
Encoding of sensory inputs in the cortex is characterized by sparse neuronal network activation. Optogenetic stimulation has previously been combined with fMRI (ofMRI) to probe functional networks. However, for a quantitative optogenetic probing of sensory-driven sparse network activation, the level of similarity between sensory and optogenetic network activation needs to be explored. Here, we complement ofMRI with optic fiber-based population Ca2+ recordings for a region-specific readout of neuronal spiking activity in rat brain. Comparing Ca2+ responses to the blood oxygenation level-dependent signal upon sensory stimulation with increasing frequencies showed adaptation of Ca2+ transients contrasted by an increase of blood oxygenation level-dependent responses, indicating that the optical recordings convey complementary information on neuronal network activity to the corresponding hemodynamic response. To study the similarity of optogenetic and sensory activation, we quantified the density of cells expressing channelrhodopsin-2 and modeled light propagation in the tissue. We estimated the effectively illuminated volume and numbers of optogenetically stimulated neurons, being indicative of sparse activation. At the functional level, upon either sensory or optogenetic stimulation we detected single-peak short-latency primary Ca2+ responses with similar amplitudes and found that blood oxygenation level-dependent responses showed similar time courses. These data suggest that ofMRI can serve as a representative model for functional brain mapping.
NeuroImage | 2016
Saeedeh Amirmohseni; Daniel Segelcke; Sylvia U. Reichl; Lydia Wachsmuth; Dennis Görlich; Cornelius Faber; Esther M. Pogatzki-Zahn
Underlying mechanisms of hyperalgesia differ with regard to the pain entities, which are well-modeled in animals for systematic studies. However, neuroimaging in different animal pain models often lacks clinical relevance and consistency with behavioral studies, which hinders the translation of results. Whereas mechanical stimulation is commonly used to explore hyperalgesia in animals and humans, functional magnetic resonance imaging (fMRI) studies frequently use electrical or heat stimuli to evaluate brain responses relevant to pain and hyperalgesia. To characterize the magnetic resonance (MR) representations of mechanical hyperalgesia after incision and inflammation, we aimed to investigate whole brain functional activities during innocuous and noxious mechanical or electrical stimulation (IMS/NMS; IES/NES), as well as metabolite levels in the thalamus of rats at rest and during electrical stimulation. In behavioral experiments, animal models of pain showed significant mechanical hyperalgesia, with a peak 24h after both injuries, but lasting longer after inflammation. In imaging experiments, mechanical and electrical stimulation revealed a biphasic BOLD response upon noxious stimulation in pain models. Analyses of the BOLD signal changes revealed significantly higher activation in pain models compared to sham animals. Furthermore, significant differences were present upon NMS (but not NES) between incision and inflammation models in all the studied regions except for contralateral somatosensory cortex (S1) and cerebellum (Cb) (Fs>4.14, ps<0.05). Additionally, MS (but not ES) induced unexpected bilateral activation of S1 in all three animal groups. Finally, MR spectroscopy (MRS) in the thalamus showed higher concentrations of gamma-aminobutyric acid in both pain models at rest and during stimulation. We conclude that employment of MS in fMRI studies could provide an informative correlate of mechanical hyperalgesia in inflammatory and incisional pain models and might be used to further assess mechanisms and treatments relevant for these clinical pain states.
Experimental Neurology | 2013
Kerstin Göbel; Jan-Hendrik Wedell; Alexander M. Herrmann; Lydia Wachsmuth; Susann Pankratz; Stefan Bittner; Thomas Budde; Christoph Kleinschnitz; Cornelius Faber; Heinz Wiendl; Sven G. Meuth
Neuropathological changes following demyelination in multiple sclerosis (MS) lead to a reorganization of axolemmal channels that causes conduction changes including conduction failure. Pharmacological modulation of voltage-sensitive potassium channels (K(V)) has been found to improve conduction in experimentally induced demyelination and produces symptomatic improvement in MS patients. Here we used an animal model of autoimmune inflammatory neurodegeneration, namely experimental autoimmune encephalomyelitis (EAE), to test the influence of the K(V)-inhibitor 4-aminopyridine (4-AP) on various disease and immune parameters as well as mobility in MOG₃₅₋₅₅ immunized C57Bl/6 mice. We challenged the hypothesis that 4-AP exerts relevant immunomodulatory or neuroprotective properties. Neither prophylactic nor therapeutic treatment with 4-AP altered disease incidence or disease course of EAE. Histopathological signs of demyelination and neuronal damage as well as MRI imaging of brain volume changes were unaltered. While application of 4-AP significantly reduced the standing outward current of stimulated CD4(+) T cells compared to controls, it failed to impact intracellular calcium concentrations in these cells. Compatibly, KV channel inhibition neither influenced CD4(+) T cell effector functions (proliferation, IL17 or IFNγ production). Importantly however, despite equal disease severity scores 4-AP treated animals showed improved mobility as assessed by 2 independent methods, 1) foot print and 2) rotarod analysis (0.332 ± 0.03, n=7 versus 0.399 ± 0.08, n=14, p<0.001, respectively). Our data suggest that 4-AP while having no apparent immunomodulatory or direct neuroprotective effects, significantly ameliorates conduction abnormalities thereby improving gait and coordination. Improvement of mobility in this experimental model supports trial data and clinical experience with 4-AP in the symptomatic treatment of MS.
Journal of Magnetic Resonance Imaging | 2015
Sabrina Doblas; Gilberto S. Almeida; François Xavier Blé; Philippe Garteiser; Benjamin A. Hoff; Dominick J.O. McIntyre; Lydia Wachsmuth; Thomas L. Chenevert; Cornelius Faber; John R. Griffiths; Andreas H. Jacobs; David M. Morris; James P B O'Connor; Simon P. Robinson; Bernard E. Van Beers; John C. Waterton
To evaluate between‐site agreement of apparent diffusion coefficient (ADC) measurements in preclinical magnetic resonance imaging (MRI) systems.